CrossAssetDataThe Company File
···
CTKB

Cytek Biosciences, Inc.

Cytek Biosciences, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Fremont, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $201 million and a loss of $67 million (its filed statements).

Product business Laboratory Analytical Instruments Fremont, CA filings since 2020 9 of 9 filed
Ask the desk about CTKB → Compare CTKB with QTRX → Price chart on TradingView ↗ Full EDGAR file ↗ Watch CTKB →

Sector peers: QTRXLABEYPTSEER

5.8/10headline grade
vs its business-model standard
7.3/10past 5.8/10present 4.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3826, Laboratory Analytical Instruments); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.8 out of ten, 9 of 9 metrics filed: past 7.3 out of ten, present 5.8 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 5.9 out of ten. 2 warning events since 2020; the latest 2024-03-01. 59th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 7.7 out of ten. +16.8% a year over 6 filed years; profitable in 3 of 6. 77th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 8.7 out of ten. Share count shrank 2.7% a year. 100% of cash flow returned. Insiders: 0 sales, 0 purchases. 87th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 6.3 out of ten. ROE -19%: lost 19¢ per shareholder dollar. Leverage 26%: owes 26¢ per asset dollar. 63rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 5.7 out of ten. top 43% of 21 in its family; net margin -33%. 57th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.0 out of ten. bottom 50% of 21 in its family for leadership; chief executive since 2021. 50th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.4 out of ten. top 46% of 21 in its family for room to expand. 54th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.0 out of ten. bottom 40% of 21 in its family for growth drivers. 40th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 1.8 out of ten. bottom 18% of 20 in its family for expectations against reality. 18th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 8-K, 2026-09-29. Filings on record since 2020. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Product 72%, Service 28%. By geography: United States 47%, EMEA 28%, APAC 20%, Other 5%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Jiang, Wenbin (PRESIDENT AND CEO); Mccombe, William D. (Chief Financial Officer); Yan, Ming (CHIEF TECHNOLOGY OFFICER); Feuchtwang, Ilan (Chief Legal Officer, Secretary); Barnett, Valerie (CHIEF LEGAL OFFICER); Busque, Philippe (SVP, GLOBAL SALES AND SERVICES); Chin, Richard (director); Holder, Michael (director); Muir, Glenn P (director); Ball, Jack (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.